1. Home
  2. ANDE vs NRIX Comparison

ANDE vs NRIX Comparison

Compare ANDE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Andersons Inc. (The)

ANDE

Andersons Inc. (The)

HOLD

Current Price

$68.85

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.58

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANDE
NRIX
Founded
1947
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ANDE
NRIX
Price
$68.85
$15.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
13
Target Price
$65.00
$29.46
AVG Volume (30 Days)
285.0K
1.1M
Earning Date
02-17-2026
01-28-2026
Dividend Yield
1.16%
N/A
EPS Growth
N/A
N/A
EPS
2.13
N/A
Revenue
$11,595,817,000.00
$83,980,000.00
Revenue This Year
$6.52
N/A
Revenue Next Year
$3.73
$28.52
P/E Ratio
$32.39
N/A
Revenue Growth
2.19
53.95
52 Week Low
$31.03
$8.18
52 Week High
$70.06
$22.50

Technical Indicators

Market Signals
Indicator
ANDE
NRIX
Relative Strength Index (RSI) 74.49 39.86
Support Level $67.30 $15.33
Resistance Level $70.06 $16.97
Average True Range (ATR) 1.83 1.04
MACD 0.29 -0.18
Stochastic Oscillator 80.62 15.39

Price Performance

Historical Comparison
ANDE
NRIX

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: